Natera, Inc. (NASDAQ:NTRA) Shares Sold by Xponance Inc.

Xponance Inc. trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,971 shares of the medical research company’s stock after selling 186 shares during the quarter. Xponance Inc.’s holdings in Natera were worth $2,528,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. CIBC Asset Management Inc raised its stake in Natera by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after purchasing an additional 111 shares during the last quarter. Natixis Advisors LLC raised its holdings in Natera by 26.3% in the 3rd quarter. Natixis Advisors LLC now owns 31,051 shares of the medical research company’s stock valued at $3,942,000 after buying an additional 6,467 shares during the period. Commerce Bank acquired a new position in shares of Natera in the 3rd quarter worth approximately $286,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Natera during the third quarter worth $9,157,000. Finally, Advisors Asset Management Inc. boosted its stake in shares of Natera by 17.6% in the third quarter. Advisors Asset Management Inc. now owns 4,778 shares of the medical research company’s stock valued at $607,000 after purchasing an additional 714 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 663 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 24,861 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the sale, the insider now owns 140,684 shares in the company, valued at approximately $23,208,639.48. This represents a 15.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 307,466 shares of company stock valued at $49,047,655. 7.60% of the stock is owned by corporate insiders.

Natera Trading Up 1.0 %

NASDAQ:NTRA opened at $151.15 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock’s 50 day simple moving average is $161.23 and its 200-day simple moving average is $149.50. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The firm has a market cap of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. Canaccord Genuity Group restated a “buy” rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a report on Friday, February 28th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Barclays initiated coverage on Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.